Vasopressin receptor antagonists, heart failure, and polycystic kidney disease

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 195-210

  Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

aquaretics; baroreceptors; osmoreceptors; vaptans; vasopressin V1a receptor; vasopressin V2 receptor

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; MOZAVAPTAN; PLACEBO; SATAVAPTAN; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN RECEPTOR;

ARTICLE; DRUG SAFETY; HEART FAILURE; HEMATURIA; HUMAN; KIDNEY PAIN; KIDNEY POLYCYSTIC DISEASE; PRESSORECEPTOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY TRACT INFECTION; VASOPRESSIN RELEASE; POLYCYSTIC KIDNEY DISEASES;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; HEART FAILURE; HUMANS; POLYCYSTIC KIDNEY DISEASES; RECEPTORS, VASOPRESSIN;

EID: 84921340628     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050913-022838     Document Type: Article

References (96)

1. Yamamura Y, Ogawa H, Chihara T, et al. 1991. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252:572-74
2. Yamamura Y, Ogawa H, Yamashita H, et al. 1992. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressinV2 receptor antagonist.Br. J. Pharmacol. 105:787-91
3. Ohnishi A, Orita Y, Okahara R, et al. 1993. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 92:2653-59
4. Serradeil-Le Gal C, Wagnon J, Garcia C, et al. 1993. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 92:224-31
5. Braunwald E. 2013. Heart failure. JACC Heart Failure 1:1-20
6. Schrier RW, Abraham WT. 1999. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341:577-85
7. Schrier RW. 2009. Renal volume, renin-Angiotensin-Aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 20:1888-93
8. Klein IH, Ligtenberg G, Oey PL, et al. 2001. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J. Am. Soc. Nephrol. 12:2427-33
9. Grassi G, Bertoli S, Seravalle G. 2012. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 21:46-51
10. Boertien WE, Meijer E, Li J, et al. 2013. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am. J. Kidney Dis. 61:420-29
11. MillerWL, Grill DE, Struck J, Jaffe AS. 2013. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am. J. Cardiol. 111:880-85
12. Marks AR. 2013. Calcium cycling proteins and heart failure:mechanisms and therapeutics. J. Clin. Invest. 123:46-52
13. Yan C, Miller CL, Abe J. 2007. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ. Res. 100:489-501
14. Paavola J, Schliffke S, Rossetti S, et al. 2013. Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy. J. Mol. Cell. Cardiol. 58:199-208
15. Anyatonwu GI, Estrada M, Tian X, et al. 2007. Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc. Natl. Acad. Sci. USA 104:6454-59
16. WeberKH, LeeEK, Basavanna U, et al. 2008. Heterologous expression of polycystin-1 inhibits endoplasmic reticulum calcium leak in stably transfected MDCK cells. Am. J. Physiol. Ren. Physiol. 294:F1279-86
17. Torres VE, Harris PC. 2014. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J. Am. Soc. Nephrol. 25:18-32
18. Grimmelikhuijzen CJ, Hauser F. 2012. Mini-review: the evolution of neuropeptide signaling. Regul. Pept. 177(Suppl.):S6-9
19. Beets I, Janssen T, Meelkop E, et al. 2012. Vasopressin/oxytocin-related signaling regulates gustatory associative learning in C. elegans. Science 338:543-45
20. Garrison JL, Macosko EZ, Bernstein S, et al. 2012. Oxytocin/vasopressin-related peptides have an ancient role in reproductive behavior. Science 338:540-43
21. Antunes-Rodrigues J, de Castro M, Elias LL, et al. 2004. Neuroendocrine control of body fluid metabolism. Physiol. Rev. 84:169-208
22. Morgenthaler NG, Struck J, Alonso C, Bergmann A. 2006. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52:112-19
23. Koshimizu TA, Nakamura K, Egashira N, et al. 2012. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol. Rev. 92:1813-64
24. Juul KV, Bichet DG, Nielsen S, Norgaard JP. 2014. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am. J. Physiol. Ren. Physiol. 306:F931-40
25. Share L. 1988. Role of vasopressin in cardiovascular regulation. Physiol. Rev. 68:1248-84
26. Goldsmith SR, Gheorghiade M. 2005. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46:1785-91
27. Francis GS, Benedict C, Johnstone DE, et al. 1990. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-29
28. Lanfear DE, Sabbah HN, Goldsmith SR, et al. 2013. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ. Heart Fail. 6:47-52
29. ZhuW, Tilley DG, MyersVD, et al. 2014. Increased vasopressin 1A receptor expression in failing human hearts. J. Am. Coll. Cardiol. 63:375-76
30. Li X, Chan TO, Myers V, et al. 2011. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation 124:572-81
31. Tahara A, Tomura Y, Wada KI, et al. 1997. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282:301-8
32. Yamamura Y, Nakamura S, Itoh S, et al. 1998. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287:860-67
33. Albright JD, Reich MF, Delos Santos EG, et al. 1998. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2, 1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 41:2442-44
34. Naitoh M, Suzuki H, Murakami M, et al. 1994. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. 267:H2245-54
35. Udelson JE, SmithWB, HendrixGH, et al. 2001. Acute hemodynamic effects of conivaptan, a dualV(1A) andV(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417-23
36. Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. 2011. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J. Card. Fail. 17:982-89
37. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. 2006. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Ren. Physiol. 290:F273-78
38. Udelson JE, Orlandi C, Ouyang J, et al. 2008. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 52:1540-45
39. Onogawa T, Sakamoto Y, Nakamura S, et al. 2011. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc.Drugs Ther./Sponsored Int. Soc. Cardiovasc. Pharmacother. 25(Suppl. 1):S67-76
40. Veeraveedu PT, Watanabe K, Ma M, et al. 2007. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem. Pharmacol. 74:1466-75
41. Veeraveedu PT, Watanabe K, Ma M, et al. 2008. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem. Pharmacol. 75:1322-30
42. Yamazaki T, Izumi Y, Nakamura Y, et al. 2012. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ. Heart Fail. 5:794-802
43. Yamazaki T, Nakamura Y, ShiotaM, et al. 2013. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J. Pharmacol. Sci. 123:58-66
44. MorookaH, Iwanaga Y, Tamaki Y, et al. 2012. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ. Heart Fail. 5:484-92
45. Ishikawa M, Kobayashi N, Sugiyama F, et al. 2013. Renoprotective effect of vasopressin V2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int. Heart J. 54:98-106
46. Udelson JE, McGrew FA, Flores E, et al. 2007. Multicenter, randomized, double-blind, placebocontrolled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49:2151-59
47. Gheorghiade M, GattisWA, O'Connor CM, et al. 2004. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291:1963-71
48. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. 2007. Short-Term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297:1332-43
49. KonstamMA, GheorghiadeM, Burnett JC Jr, et al. 2007. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319-31
50. US Food and Drug Administration. 2012. September 13, 2012: Cardiovascular and Renal Drugs Advisory Committee meeting announcement. http://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273. htm
51. Rossi J, Bayram M, Udelson JE, et al. 2007. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 9:82-86
52. Filippatos G, Rossi J, Lloyd-Jones DM, et al. 2007. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J. Card. Fail. 13:360-64
53. Hauptman PJ, Burnett J, GheorghiadeM, et al. 2013. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J. Card. Fail. 19:390-97
54. Vaduganathan M, Gheorghiade M, Pang PS, et al. 2012. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J. Cardiovasc. Med. 13:415-22
55. Feldman AM, Hamad E, Tsai EJ, et al. 2014. Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data. Clin. Pharmacol. Ther. 95:373-75
56. Kinugawa K, Imamura T, Komuro I. 2013. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin. Pharmacol. Ther. 94:449-51
57. Yamaguchi T, Nagao S, Kasahara M, et al. 1997. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am. J. Kidney Dis. 30:703-9
58. Gattone VH, Wang X, Harris PC, Torres VE. 2003. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9:1323-26
59. Smith LA, Bukanov NO, Husson H, et al. 2006. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J. Am. Soc. Nephrol. 17:2821-31
60. Starremans PG, Li X, Finnerty PE, et al. 2008. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5-end of Pkd1. Kidney Int. 73:1394-405
61. Hopp K, Ward CJ, Hommerding CJ, et al. 2012. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J. Clin. Invest. 122:4257-73
62. Wang X, Ward CJ, Harris PC, TorresVE. 2010. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int. 77:129-40
63. Rees S, KittikulsuthW, Roos K, et al. 2014. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J. Am. Soc. Nephrol. 25:232-37
64. Ye H, Wang X, Sussman CR, et al. 2012. Genetic approach to evaluate the role of the PDE3 subfamilies in polycystic kidney disease (PKD). Presented at ASN Kidney Week, San Diego, CA
65. Talbot JJ, Song X, Wang X, et al. 2014. The cleaved cytoplasmic tail of polycystin-1 regulates Srcdependent STAT3 activation. J. Am. Soc. Nephrol. 25:1737-48
66. MutigK, Paliege A, Kahl T, et al. 2007. VasopressinV2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am. J. Physiol. Ren. Physiol. 293:F1166-F77
67. Carmosino M, Brooks HL, Cai Q, et al. 2007. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am. J. Physiol. Ren. Physiol. 292:F351-60
68. Yasuda G, Jeffries WB. 1998. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int. 54:80-86
69. Wang X, Wu Y, Ward CJ, et al. 2008. Vasopressin directly regulates cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19:102-8
70. Nagao S, Nishii K, Katsuyama M, et al. 2006. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 17:2220-27
71. Gattone VH, Maser RL, Tian C, et al. 1999. Developmental expression of urine concentration-Associated genes and their altered expression in murine infantile-Type polycystic kidney disease. Dev. Gen. 24:309-18
72. Aihara M, Fujiki H, Mizuguchi H, et al. 2014. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J. Pharmacol. Exp. Ther. 349:258-67
73. Wang X, Gattone V 2nd, Harris PC, Torres VE. 2005. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 16:846-51
74. Torres VE, Wang X, Qian Q, et al. 2004. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10:363-64
75. Meijer E, Gansevoort RT, de Jong PE, et al. 2011. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol. Dial. Transplant. 26:2445-53
76. Hopp K, Hommerding CJ, Wang X, et al. 2014. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J. Am. Soc. Nephrol. In press
77. Reif GA, Yamaguchi T, Nivens E, et al. 2011. Tolvaptan inhibits ERK-dependent cell proliferation, Cl-secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Ren. Physiol. 301:F1005-13
78. Torres VE. 2008. Role of vasopressin antagonists. Clin. J. Am. Soc. Nephrol. 3:1212-18
79. Higashihara E, Torres VE, Chapman AB, et al. 2011. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin. J. Am. Soc. Nephrol. 6:2499-507
80. Irazabal MV, Torres VE, Hogan MC, et al. 2011. Short-Term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 80:295-301
81. Boertien WE, Meijer E, de Jong PE, et al. 2013. Short-Term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 84:1278-86
82. Torres VE, Meijer E, Bae KT, et al. 2011. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am. J. Kidney Dis. 57:692-99
83. Torres VE, Chapman AB, Devuyst O, et al. 2012. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367:2407-18
84. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. 2009. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. http://www.fda.gov/downloads/Drugs/. . ./Guidances/UCM174090.pdf
85. US Food and Drug Administration 2013. Cardiovascular and renal drugs advisory committee meeting announcement. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm357806.htm
86. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. 2014. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. In press
87. Bankir L, Bouby N, Ritz E. 2013. Vasopressin: a novel target for the prevention and retardation of kidney disease?. Nat. Rev. Nephrol. 9:223-39
88. Bouby N, Bachmann S, Bichet D, Bankir L. 1990. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 258:F973-79
89. Bouby N, Hassler C, Bankir L. 1999. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci. 65:991-1004
90. Bardoux P, Martin H, Ahloulay M, et al. 1999. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc. Natl. Acad. Sci. USA 96:10397-402
91. Sugiura T, Yamauchi A, Kitamura H, et al. 1999. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-b. Kidney Int. 55:1800-10
92. Perico N, Coja C, Corna D, et al. 2009. V1/V2 vasopressin receptor antagonism potentiates renoprotection of renin-Angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 76:960-67
93. Clark WF, Sontrop JM, Macnab JJ, et al. 2011. Urine volume and change in estimated GFR in a community-based cohort study. Clin. J. Am. Soc. Nephrol. 6:2634-41
94. Strippoli GF, Craig JC, Rochtchina E, et al. 2011. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 16:326-34
95. Sontrop JM, Dixon SN, Garg AX, et al. 2013. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am. J. Nephrol. 37:434-42
96. Plischke M, Kohl M, Bankir L, et al. 2014. Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort-A possible titration target?. PLOS ONE 9:e93226